TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

Launched by MAYO CLINIC · Aug 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a protein called TRPC6 to see if it can help predict and prevent heart problems caused by chemotherapy in patients with breast cancer. Some cancer treatments can harm the heart, leading to issues like heart failure. By understanding how these treatments affect the heart at a genetic level, researchers hope to find ways to protect patients and improve their long-term heart health.

To participate in this trial, you need to be at least 18 years old and starting certain chemotherapy treatments, like doxorubicin or trastuzumab. You should be able to understand the study's requirements and give your consent to join. If you join, you will provide blood samples, which will help researchers learn more about heart-related changes during treatment. This study is currently looking for volunteers, and it's open to all genders. If you're interested, it's a chance to contribute to important research that could help many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Any breast cancer patient initiating doxorubicin/other anthracycline and patients receiving trastuzumab without doxorubicin/anthracycline in the neoadjuvant/adjuvant setting
• • An understanding of the protocol and its requirements, risks, and discomforts
• • The ability and willingness to sign an informed consent
• • Diagnosed with therapy related cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment OR completed chemotherapy with no cardiotoxicity at least two years post treatment OR patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include doxorubicin chemotherapy, or trastuzumab.
• • Healthy, non-pregnant, adult subjects who weigh at least 110 pounds
• Exclusion Criteria:
• • Inability on the part of the patient to understand the informed consent or be compliant with the protocol
• • Anemia with hemoglobin less than 8
• • Patients not willing to undergo a blood draw
• • Patients with stage IV or distant metastatic breast cancer